First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia.
First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China;
Hepatobiliary Surg Nutr. 2013 Aug;2(4):209-15. doi: 10.3978/j.issn.2304-3881.2013.06.07.
Hepatocellular carcinoma (HCC) is a highly vascular tumor that expresses vascular endothelial growth factor (VEGF). Various studies have evaluated the prognostic value of VEGF levels in HCC, but yielded conflicting results.
Electronic databases updated to June 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between serum VEGF level and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed.
We performed a meta-analysis of 11 studies that evaluated the correlation between serum VEGF level and survival in patients with HCC. Combined hazard ratios suggested that serum VEGF level had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.88, 95% confidence interval (CI): 1.46-2.30], and disease free survival (DFS) (HR=2.27, 95% CI: 1.55-2.98) in patients with HCC. No significant heterogeneity was observed among all studies.
Serum high VEGF level indicates a poor prognosis for patients with hepatocellular carcinoma.
肝细胞癌（HCC）是一种高度血管化的肿瘤，表达血管内皮生长因子（VEGF）。多项研究评估了 HCC 患者 VEGF 水平的预后价值，但结果存在争议。
检索至 2013 年 6 月的电子数据库，以寻找相关研究。对定量评估 HCC 患者血清 VEGF 水平与生存关系的合格研究进行荟萃分析。汇总并定量分析生存数据。
我们对 11 项评估 HCC 患者血清 VEGF 水平与生存相关性的研究进行了荟萃分析。合并风险比表明，血清 VEGF 水平对 HCC 患者的总生存（OS）[风险比（HR）=1.88，95%置信区间（CI）：1.46-2.30]和无病生存（DFS）（HR=2.27，95%CI：1.55-2.98）有不利影响。所有研究之间均无显著异质性。
血清高 VEGF 水平提示 HCC 患者预后不良。
